Venus Remedies Ltd

Venus Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 24 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 September 2026, providing investors with an up-to-date view of the company’s performance and outlook.

At Rs 1701.9, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Venus Remedies Ltd locked at its upper circuit of 5% on 3 Sep 2026, with buyers queuing and no sellers willing to part with shares.

Venus Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 24 August 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 25 August 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

At Rs 1,681.4, sellers were still queuing — but there were no buyers willing to take the other side. Venus Remedies Ltd locked at its lower circuit of 5%, the maximum loss allowed in a single session on 20 Aug 2026, with unfilled sell orders and a frozen price.

Venus Remedies Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting evolving market perceptions amid robust financial performance and sector dynamics. This article analyses the recent changes in key valuation metrics such as price-to-earnings (P/E) and price-to-book value (P/BV) ratios, comparing them with historical averages and peer benchmarks to assess the stock’s price attractiveness.

At Rs 1,790, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Venus Remedies Ltd locked at its upper circuit of 3.8% on 14 Aug 2026, with buyers queuing and no sellers willing to part with shares.

Venus Remedies Ltd has been upgraded from a Hold to a Buy rating following a comprehensive reassessment of its technical indicators, valuation metrics, financial trends, and overall quality. The company’s recent performance, both on the charts and in its quarterly results, has prompted this positive revision, signalling renewed investor confidence in its growth trajectory within the Pharmaceuticals & Biotechnology sector.

Venus Remedies Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by a combination of technical indicators including MACD, RSI, moving averages, and Bollinger Bands, signalling renewed investor interest and potential upside in the Pharmaceuticals & Biotechnology sector.

At Rs 1,726, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Venus Remedies Ltd locked at its upper circuit of 5% on 13 Aug 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 1,647.10, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Venus Remedies Ltd locked at its upper circuit of 5% on 12 Aug 2026, with buyers queuing and no sellers willing to part with shares.

Venus Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 11 August 2026. This change reflects a reassessment of the company’s valuation metrics amid robust financial performance and positive technical indicators, prompting a more cautious stance despite impressive returns and growth.

Venus Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change reflects evolving market perceptions amid strong stock performance and sector-wide valuation trends, prompting a reassessment of its price attractiveness relative to peers and historical benchmarks.

Venus Remedies Ltd has seen its investment rating upgraded from Hold to Buy, driven primarily by an improved valuation profile and robust financial performance. The company’s micro-cap status, combined with strong operational metrics and technical signals, underpins this positive reassessment by MarketsMOJO as of 5 August 2026.

Venus Remedies Ltd has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating, supported by robust financial metrics and a compelling growth trajectory. This micro-cap pharmaceutical player now presents a more enticing price proposition relative to its historical averages and peer group, signalling renewed investor interest and potential upside.

At Rs 1,509.3, sellers were still queuing — but there were no buyers willing to take the other side. Venus Remedies Ltd locked at its lower circuit of 3.99% on 28 Jul 2026, with unfilled sell orders and a frozen price that capped losses for the day.